MedTrace Logo

Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

NCT06765265 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2025-03-11

No results posted yet for this study

Summary

there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months

Conditions

  • Acute Coronary Syndromes

Interventions

DRUG

Rosuvastatin 20 mg/day

Rosuvastatin 20 mg / Day for 24 weeks

DRUG

Atorvastatin 40 mg

Atorvastatin 40mg / Day for 24 weeks

Sponsors & Collaborators

  • King Edward Medical University

    lead OTHER

Principal Investigators

  • Uzma Malik · King Edward Medical University

  • Ali Hussnain · King Edward Medical University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-05
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765265 on ClinicalTrials.gov